Findings of Research Misconduct, 34016 [E7-11908]
Download as PDF
<![CDATA[
34016
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
Carlos A. Murillo, M.D., University of
Texas Medical Branch at Galveston:
Based on the report of an inquiry
conducted by the University of Texas
Medical Branch at Galveston (UTMB)
and additional analysis and information
obtained by the Office of Research
Integrity during its oversight review, the
U.S. Public Health Service (PHS) found
that Carlos A. Murillo, M.D., former
Surgical Resident, Department of
Surgery, UTMB, engaged in research
misconduct in research supported by
National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK),
National Institutes of Health (NIH),
grants R01 DK48498 and T32 DK07639.
Specifically, Dr. Murillo falsified
research on the amelioration by
antisense RNA (siRNA) of dextraninduced colonic toxicity in mice. He
altered the concentrations of dextran
solution fed to mice to induce colonic
inflammation, by intentionally
including little or no dextran in the
drinking water of siRNA treated mice,
so that the animals that received siRNA
would have few or no colonic lesions.
Dr. Murillo has entered into a
Voluntary Exclusion Agreement
(Agreement) in which he has voluntarily
agreed, for a period of three (3) years,
beginning on May 30, 2007:
(1) That any institution that submits
an application for PHS support for a
research project on which Dr. Murillo’s
participation is proposed or that uses
him in any capacity on PHS support
research, or that submits a report of
PHS-funded research in which he is
involved, must concurrently submit a
plan for supervision of his duties to the
funding agency for approval; the
supervisory plan must be designed to
ensure the scientific integrity of Dr.
Murillo’s research contribution; Dr.
Murillo agrees to ensure that a copy of
the supervisory plan is also submitted to
ORI by the institution and agrees that he
will not participate in any PHSsupported research until such a
supervision plan is submitted to ORI;
(2) to exclude himself from serving in
any advisory capacity to PHS, including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant;
and
(3) to request retraction of the abstract
entitled ‘‘Inhibition of Phosphoinositol
3-kinase Using Anti-p85 siRNA
Attenuates Dextran-Sulfate-Induced
Inflammatory Bowel Disease’’
(Gastroenterology 126:A49, 2004), by
signing the letter of retraction prepared
by ORI attached as Attachment 2 and
made part of the Agreement.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
John Dahlberg,
Acting Director,Office of Research Integrity.
[FR Doc. E7–11908 Filed 6–19–07; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day-07–06BF]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–6974. Written
Proposed Project
Assessment and Evaluation of the
Role of Care Coordination (Case
Management) in Improving Access and
Care within the Spina Bifida Clinic
System—New—National Center for
Birth Defects and Developmental
Disabilities (NCBDDD), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
CDC is requesting a one-year approval
from the Office of Management and
Budget to collect information about the
effectiveness of care coordination for
patients with spina bifida. Studies have
shown that care coordination is
beneficial for individuals with complex
health conditions such as cystic fibrosis
and sickle cell anemia, however, the
extent to which care coordination is
effective for assisting individuals with
spina bifida is unknown. Spina bifida is
one of the most common birth defects,
affecting approximately 3 per 10,000
live births in the United States annually.
The proposed activity is part of the
National Spina Bifida Program
mandated in Section 317C of the Public
Health Service Act (42 U.S.C. 247b–4).
Researchers will visit 10 spina bifida
clinics nationwide. At each clinic, one
focus group will be conducted with
approximately eight caregivers of
children with spina bifida. Each focus
group will last about two hours. In
addition, interviews will be conducted
with approximately five staff members
at each clinic; each interview will take
approximately 45 minutes. Focus group
and interview respondents will be asked
a variety of questions related to care
coordination for individuals with spina
bifida including how care is coordinated
in the clinic, barriers and facilitators to
the provision of care coordination, the
effectiveness of care coordination, and
recommendations for improving care
coordination.
There will be no costs to the
respondents other than their time. The
total estimated annualized burden hours
are 244.
Estimated Annualized Burden Hours:
Number of
respondents
Type of respondents
rwilkins on PROD1PC63 with NOTICES
comments should be received within 30
days of this notice.
Form name
Caregivers for Spina Bifida Patients ...............
Focus Group Response Form .......................
Focus Group Telephone Script ......................
Focus Group Moderator’s Guide ...................
Clinic Recruitment Script ................................
Clinic Staff Telephone Interview Script ..........
Spina Bifida Clinic Staff ..................................
VerDate Aug<31>2005
18:25 Jun 19, 2007
Jkt 211001
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
E:\FR\FM\20JNN1.SGM
100
100
80
14
55
20JNN1
Number of
reponses per
respondent
1
1
1
1
1
Average
burden per
response
(in hours)
5/60
15/60
2
15/60
10/60
]]>Agencies
[Federal Register Volume 72, Number 118 (Wednesday, June 20, 2007)]
[Notices]
[Page 34016]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-11908]
[[Page 34016]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
Carlos A. Murillo, M.D., University of Texas Medical Branch at
Galveston: Based on the report of an inquiry conducted by the
University of Texas Medical Branch at Galveston (UTMB) and additional
analysis and information obtained by the Office of Research Integrity
during its oversight review, the U.S. Public Health Service (PHS) found
that Carlos A. Murillo, M.D., former Surgical Resident, Department of
Surgery, UTMB, engaged in research misconduct in research supported by
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institutes of Health (NIH), grants R01 DK48498 and
T32 DK07639.
Specifically, Dr. Murillo falsified research on the amelioration by
antisense RNA (siRNA) of dextran-induced colonic toxicity in mice. He
altered the concentrations of dextran solution fed to mice to induce
colonic inflammation, by intentionally including little or no dextran
in the drinking water of siRNA treated mice, so that the animals that
received siRNA would have few or no colonic lesions.
Dr. Murillo has entered into a Voluntary Exclusion Agreement
(Agreement) in which he has voluntarily agreed, for a period of three
(3) years, beginning on May 30, 2007:
(1) That any institution that submits an application for PHS
support for a research project on which Dr. Murillo's participation is
proposed or that uses him in any capacity on PHS support research, or
that submits a report of PHS-funded research in which he is involved,
must concurrently submit a plan for supervision of his duties to the
funding agency for approval; the supervisory plan must be designed to
ensure the scientific integrity of Dr. Murillo's research contribution;
Dr. Murillo agrees to ensure that a copy of the supervisory plan is
also submitted to ORI by the institution and agrees that he will not
participate in any PHS-supported research until such a supervision plan
is submitted to ORI;
(2) to exclude himself from serving in any advisory capacity to
PHS, including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant; and
(3) to request retraction of the abstract entitled ``Inhibition of
Phosphoinositol 3-kinase Using Anti-p85 siRNA Attenuates Dextran-
Sulfate-Induced Inflammatory Bowel Disease'' (Gastroenterology 126:A49,
2004), by signing the letter of retraction prepared by ORI attached as
Attachment 2 and made part of the Agreement.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
John Dahlberg,
Acting Director,Office of Research Integrity.
[FR Doc. E7-11908 Filed 6-19-07; 8:45 am]
BILLING CODE 4150-31-P
